Latent tuberculosis infections in hard-to-reach drug using population - detection, prevention and control

Tuberculosis

Volumn 89, Issue SUPPL.1, 2009, Pages

  Hwang, Lu Yu ^a   Grimes, Carolyn Z ^a   Beasley, R Palmer ^a   Graviss, Edward A ^a,b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Drug users; Interferon gamma release assay; Latent tuberculosis infection; QFT; T SPOT

Indexed keywords

GAMMA INTERFERON;

ARTICLE; BACTERIUM DETECTION; CYTOKINE RELEASE; DRUG USE; FOLLOW UP; HUMAN; INFECTION PREVENTION; LATENT PERIOD; PRIORITY JOURNAL; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

DRUG USERS; EARLY DIAGNOSIS; FEMALE; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MASS SCREENING; PILOT PROJECTS; PRISONERS; SENSITIVITY AND SPECIFICITY; SUBSTANCE-RELATED DISORDERS; TEXAS; TUBERCULIN TEST;

EID: 72049112818     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(09)70010-1     Document Type: Article

References (57)

1. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 54 (2005) 1-47
2. Reichman L.B., Felton C.P., and Edsall J.R. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 139 (1979) 337-339
3. Selwyn P.A., Hartel D., Lewis V.A., Schoenbaum E.E., Vermund S.H., Klein R.S., et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320 (1989) 545-550
4. Perlman D.C., Salomon N., Perkins M.P., Yancovitz S., Paone D., and Des Jarlais D.C. Tuberculosis in drug users. Clin Infect Dis 21 (1995) 1253-1264
5. Malotte C.K., Hollingshead J.R., and Rhodes F. Monetary versus nonmonetary incentives for TB skin test reading among drug users. AmJPrevMed 16 (1999) 182-188
6. Durante A.J., Selwyn P.A., and O'Connor P.G. Risk factors for and knowledge of Mycobacterium tuberculosis infection among drug users in substance abuse treatment. Addiction 93 (1998) 1393-1401
7. Howard A.A., Klein R.S., Schoenbaum E.E., and Gourevitch M.N. Crack cocaine use and other risk factors for tuberculin positivity in drug users. Clin Infect Dis 35 (2002) 1183-1190
8. Salomon N., Perlman D.C., Friedmann P., Ziluck V., and Des Jarlais D.C. Prevalence and risk factors for positive tuberculin skin tests among active drug users at a syringe exchange program. Int J Tuberc Lung Dis 4 (2000) 47-54
9. Gourevitch M.N., Wasserman W., Panero M.S., and Selwyn P.A. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis 15 (1996) 93-104
10. Selwyn P.A., Sckell B.M., Alcabes P., Friedland G.H., Klein R.S., and Schoenbaum E.E. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 268 (1992) 504-509
11. Golub J.E., Saraceni V., Cavalcante S.C., Pachecho A.G., Moulton L.H., King B.S., et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 21 (2007) 1441-1448
12. Jansa J.M., Serrano J., Cayla J.A., Vidal R., Ocana I., and Espanol T. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis. Int J Tuberc Lung Dis 2 (1998) 140-146
13. Klein R.S., Gourevitch M.N., Teeter R., and Schoenbaum E.E. The incidence of tuberculosis in drug users with small tuberculin reaction sizes. Int J Tuberc Lung Dis 5 (2001) 707-711
14. Moss A.R., Hahn J.A., Tulsky J.P., Daley C.L., Small P.M., and Hopewell P.C. Tuberculosis in the homeless. A prospective study. Am J Respir Crit Care Med 162 (2000) 460-464
15. Keizer S.T., Langendam M.M., van Deutekom H., Coutinho R.A., and van Ameijden E.J. How does tuberculosis relate to HIV positive and HIV negative drug users?. J Epidemiol Community Health 54 (2000) 64-68
16. Guelar A., Gatell J.M., Verdejo J., Podzamczer D., Lozano L., Aznar E., et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 7 (1993) 1345-1349
17. Gourevitch M.N., Hartel D., Selwyn P.A., Schoenbaum E.E., and Klein R.S. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS 13 (1999) 2069-2074
18. Muga R., Ferreros I., Langohr K., de Ollala P.G., Del Romero J., Quintana M., et al. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS 21 (2007) 2521-2527
19. Scholten J.N., Driver C.R., Munsiff S.S., Kaye K., Rubino M.A., Gourevitch M.N., et al. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis 37 (2003) 1686-1692
20. Daley C.L., Hahn J.A., Moss A.R., Hopewell P.C., and Schecter G.F. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am J Respir Crit Care Med 157 (1998) 19-22
21. Leonhardt K.K., Gentile F., Gilbert B.P., and Aiken M. A cluster of tuberculosis among crack house contacts in San Mateo County, California. Am J Public Health 84 (1994) 1834-1836
22. Bishai W.R., Graham N.M., Harrington S., Pope D.S., Hooper N., Astemborski J., et al. Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA 280 (1998) 1679-1684
23. Klovdahl A.S., Graviss E.A., Yaganehdoost A., Ross M.W., Adams G.J., Ramaswamy S., et al. Networks and tuberculosis: an undetected community outbreak involving public places. Soc Sci Med 52 (2001) 681-694
24. Latkin C., Mandell W., Vlahov D., Oziemkowska M., and Celentano D. People and places: behavioral settings and personal network characteristics as correlates of needle sharing. J Acquir Immune Defic Syndr Hum Retrovirol 13 (1996) 273-280
25. Yaganehdoost A., Graviss E.A., Ross M.W., Adams G.J., Ramaswamy S., Wanger A., et al. Complex transmission dynamics of clonally related virulent Mycobacterium tuberculosis associated with barhopping by predominantly human immunode-ficiency virus-positive gay men. J Infect Dis 180 (1999) 1245-1251
26. Cheung R.C., Hanson A.K., Maganti K., Keeffe E.B., and Matsui S.M. Viral hepatitis and other infectious diseases in a homeless population. J Clin Gastroenterol 34 (2002) 476-480
27. Richards D.C., Mikiashvila T., Parris J.J., Kourbatova E.V., Wilson J.C., Shubladze N., et al. High prevalence of hepatitis C virus but not HIV co-infection among patients with tuberculosis in Georgia. Int J Tuberc Lung Dis 10 (2006) 396-401
28. von Pirquet C. Frequency of tuberculosis in childhood. JAMA 52 (1907) 675-678
29. American Thoracic Society and Centers for Disease Control and Prevention. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med 161 (2000) 1376-1395
30. Menzies D., Pai M., and Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146 (2007) 340-354
31. Converse P.J., Jones S.L., Astemborski J., Vlahov D., and Graham N.M. Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J Infect Dis 176 (1997) 144-150
32. Kimura M., Converse P.J., Astemborski J., Rothel J.S., Vlahov D., Comstock G.W., et al. Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. J Infect Dis 179 (1999) 1297-1300
33. Shah S.S., McGowan J.P., Klein R.S., Converse P.J., Blum S., and Gourevitch M.N. Agreement between Mantoux skin testing and QuantiFERON-TB assay using dual mycobacterial antigens in current and former injection drug users. Med Sci Monit 12 (2006) MT11-MT16
34. Fietta A., Meloni F., Cascina A., Morosini M., Marena C., Troupioti P., et al. Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control 31 (2003) 347-353
35. Mazurek G.H., LoBue P.A., Daley C.L., Bernardo J., Lardizabal A.A., Bishai W.R., et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286 (2001) 1740-1747
36. Pottumarthy S., Morris A.J., Harrison A.C., and Wells V.C. Evaluation of the tuberculin gamma interferon assay: potential to replace the Mantoux skin test. J Clin Microbiol 37 (1999) 3229-3232
37. Mazurek G.H., Jereb J., Lobue P., Iademarco M.F., Metchock B., and Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (2005) 49-55
38. Rangaka M.X., Wilkinson K.A., Seldon R., van Cutsem G., Meintjes G.A., Morroni C., et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 175 (2007) 514-520
39. Meier T., Eulenbruch H.P., Wrighton-Smith P., Enders G., and Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 24 (2005) 529-536
40. Lalvani A., Pathan A.A., McShane H., Wilkinson R.J., Latif M., Conlon C.P., et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 163 (2001) 824-828
41. Pathan A.A., Wilkinson K.A., Klenerman P., McShane H., Davidson R.N., Pasvol G., et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 167 (2001) 5217-5225
42. Harada N., Nakajima Y., Higuchi K., Sekiya Y., Rothel J., and Mori T. Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 27 (2006) 442-448
43. Lee J.Y., Choi H.J., Park I.N., Hong S.B., Oh Y.M., Lim C.M., et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 28 (2006) 24-30
44. Goletti D., Carrara S., Vincenti D., Saltini C., Rizzi E.B., Schinina V., et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. Clin Microbiol Infect 12 (2006) 544-550
45. Ferrara G., Losi M., D'Amico R., Roversi P., Piro R., Meacci M., et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367 (2006) 1328-1334
46. Ravn P., Munk M.E., Andersen A.B., Lundgren B., Lundgren J.D., Nielson L.N., et al. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 12 (2005) 491-496
47. Mori T., Sakatani M., Yamagishi F., Takashima T., Kawabe Y., Nagao K., et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 170 (2004) 59-64
48. Kang Y.A., Lee H.W., Yoon H.I., Cho B., Han S.K., Shim Y.S., et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 293 (2005) 2756-2761
49. Connell T.G., Curtis N., Ranganathan S.C., and Buttery J.P. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax 61 (2006) 616-620
50. Brock I., Munk M.E., Kok-Jensen A., and Andersen P. Performance of whole blood IFN-gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis 5 (2001) 462-467
51. Ferrara G., Losi M., Meacci M., Meccugni B., Piro R., Roversi P., et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 172 (2005) 631-635
52. Mandalakas A.M., Hesseling A.C., Chegou N.N., Kirchner H.L., Zhu X., Marais B.J., et al. High level of discordant IGRA results in HIV-infected adults and children. Int J Tuberc Lung Dis 12 (2008) 417-423
53. Dewan P.K., Grinsdale J., Liska S., Wong E., Fallstad R., and Kawamura L.M. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 6 (2006) 47
54. Grimes C.Z., Hwang L.Y., Williams M.L., Austin C.M., and Graviss E.A. Tuberculosis infection in drug users: interferon-gamma release assay performance. Int J Tuberc Lung Dis 11 (2007) 1183-1189
55. Williams M.L., Elwood W.N., Weatherby N.L., Bowen A., Zhao Z., Saunders L., et al. An assessment of the risks of syphilis and HIV infection among a sample of not-in-treatment drug users in Houston, Texas. AIDS Care 8 (1996) 671-682
56. Ross M.W., Hwang L.Y., Leonard L., Teng M., and Duncan L. Sexual behaviour, STDs and drug use in a crack house population. Int J STD AIDS 10 (1999) 224-230
57. Hwang L.Y., Ross M.W., Zack C., Bull L., Rickman K., and Holleman M. Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers. Clin Infect Dis 31 (2000) 920-926